Wird geladen...
Underutilization of prophylactic rectal indomethacin and pancreatic duct stent for prevention of post-ERCP Pancreatitis
Background and study aims Incidence of Post-ERCP pancreatitis (PEP) ranges from 1 % to 10 % in unselected patients and as high as 25 % to 30 % in high-risk patients. Rectal indomethacin administered before or immediately after an ERCP and prophylactic pancreatic duct stent placement (PPS) are assoc...
Gespeichert in:
| Veröffentlicht in: | Endosc Int Open |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Georg Thieme Verlag KG
2021
|
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8211473/ https://ncbi.nlm.nih.gov/pubmed/34222616 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/a-1460-7776 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|